glp 1 bladder issues Effects of Glucagon like Peptide-1 agonists on patients with overactive bladder: A pilot study GLP-1 Gallbladder Risk: What Clinicians
Description
Your provider monitors appetite changes, gastrointestinal tolerance, energy levels, and overall progress, making gradual adjustments to support effectiveness while minimizing side effects
10.1016/j.ajps.2019.01.002
The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs
Biol Psychiatry [Internet] Biol Psychiatry
Nausea was more frequent with tirzepatide vs placebo, especially with tirzepatide 15 mg (OR 5.60 [95% CI 3.12, 10.06]), associated with higher incidence of vomiting (OR 5.50 [95% CI 2.40, 12.59]) and diarrhoea (OR 3.31 [95% CI 1.40, 7.85])
Cell Metab (2017) 26(2):34352.e2
